Serplulimab Plus Chemotherapy, with or without HLX04, versus Chemotherapy as First-Line Treatment for Nonsquamous NSCLC: Final Survival Analysis of the Phase III ASTRUM-002 Study.

Hao X, Wang L, Hao Y, Hu Y, Chen C, Chen B, Huang Y, Zang A, Wang Y, Chen Z, Zhuang W, Shi J, Ren X, Nie L, Yu G, Luo F, Mao Y, Wang X, Li B, Bai Y, Shi J, Ni H, Hou X, Yu H, Li J, Wang Q, Zhu J, Shi Y, ASTRUM-002 Study Group

Open source

DOI: 10.34133/cancomm.0034
Published: 2026
Container: Cancer communications (London, England)
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.34133/cancomm.0034,
  title = {Serplulimab Plus Chemotherapy, with or without HLX04, versus Chemotherapy as First-Line Treatment for Nonsquamous NSCLC: Final Survival Analysis of the Phase III ASTRUM-002 Study.},
  author = {Hao X and Wang L and Hao Y and Hu Y and Chen C and Chen B and Huang Y and Zang A and Wang Y and Chen Z and Zhuang W and Shi J and Ren X and Nie L and Yu G and Luo F and Mao Y and Wang X and Li B and Bai Y and Shi J and Ni H and Hou X and Yu H and Li J and Wang Q and Zhu J and Shi Y and ASTRUM-002 Study Group},
  year = {2026},
  journal = {Cancer communications (London, England)},
  doi = {10.34133/cancomm.0034},
  url = {https://doi.org/10.34133/cancomm.0034}
}

RIS

TY  - JOUR
TI  - Serplulimab Plus Chemotherapy, with or without HLX04, versus Chemotherapy as First-Line Treatment for Nonsquamous NSCLC: Final Survival Analysis of the Phase III ASTRUM-002 Study.
AU  - Hao X
AU  - Wang L
AU  - Hao Y
AU  - Hu Y
AU  - Chen C
AU  - Chen B
AU  - Huang Y
AU  - Zang A
AU  - Wang Y
AU  - Chen Z
AU  - Zhuang W
AU  - Shi J
AU  - Ren X
AU  - Nie L
AU  - Yu G
AU  - Luo F
AU  - Mao Y
AU  - Wang X
AU  - Li B
AU  - Bai Y
AU  - Shi J
AU  - Ni H
AU  - Hou X
AU  - Yu H
AU  - Li J
AU  - Wang Q
AU  - Zhu J
AU  - Shi Y
AU  - ASTRUM-002 Study Group
PY  - 2026
JO  - Cancer communications (London, England)
DO  - 10.34133/cancomm.0034
UR  - https://doi.org/10.34133/cancomm.0034
ER  -

APA

X, H., L, W., Y, H., Y, H., C, C., B, C., Y, H., A, Z., Y, W., Z, C., W, Z., J, S., X, R., L, N., G, Y., F, L., Y, M., X, W., B, L., Y, B., J, S., H, N., X, H., H, Y., J, L., Q, W., J, Z., Y, S., & Group, A. S. (2026). Serplulimab Plus Chemotherapy, with or without HLX04, versus Chemotherapy as First-Line Treatment for Nonsquamous NSCLC: Final Survival Analysis of the Phase III ASTRUM-002 Study.. Cancer communications (London, England). https://doi.org/10.34133/cancomm.0034

Source records

pubmed · retrieved 2026-09-26T21:39:59.851Z